LivaNova PLC (NASDAQ:LIVN) Receives $64.40 Average PT from Brokerages

LivaNova PLC (NASDAQ:LIVN) has received a consensus recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $64.40.

Several research firms recently issued reports on LIVN. Mizuho reiterated a “buy” rating and set a $75.00 target price on shares of LivaNova in a research report on Wednesday, March 27th. Barclays upped their price target on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price target on shares of LivaNova in a report on Wednesday, March 20th. Finally, Robert W. Baird raised their price objective on LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research report on Thursday, February 22nd.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $55.94 on Monday. The firm’s 50 day simple moving average is $53.92 and its two-hundred day simple moving average is $50.59. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The company has a market capitalization of $3.02 billion, a P/E ratio of 174.82 and a beta of 0.89. LivaNova has a 1-year low of $42.75 and a 1-year high of $59.86.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. During the same quarter in the previous year, the company earned $0.81 EPS. LivaNova’s revenue for the quarter was up 12.8% on a year-over-year basis. Research analysts expect that LivaNova will post 3.01 EPS for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently bought and sold shares of LIVN. Arizona State Retirement System raised its position in shares of LivaNova by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 15,309 shares of the company’s stock valued at $810,000 after buying an additional 264 shares in the last quarter. State of Michigan Retirement System increased its stake in LivaNova by 2.3% during the first quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock worth $739,000 after acquiring an additional 300 shares during the last quarter. Louisiana State Employees Retirement System raised its position in LivaNova by 2.6% during the first quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company’s stock valued at $867,000 after purchasing an additional 400 shares during the period. Headlands Technologies LLC lifted its stake in shares of LivaNova by 33.3% in the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock valued at $93,000 after purchasing an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of LivaNova by 2.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,202 shares of the company’s stock worth $1,438,000 after purchasing an additional 544 shares during the period. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.